The treatment of Hodgkin's disease.
D000380:Agranulocytosis / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002699:Chlorambucil / Q000627:therapeutic use; D004338:Drug Combinations; D006689:Hodgkin Disease / Q000145:classification / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008466:Mechlorethamine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011379:Prognosis; D011879:Radiotherapy Dosage / Q000592:standards; D012075:Remission, Spontaneous; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004338:Drug Combinations; D002699:Chlorambucil; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D011241:Prednisone